Compare Aterian Inc (ATER) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs Quest Diagnostics Inc — how do they compare? Aterian Inc trades at $0.46 (market cap $5.32M), while Quest Diagnostics Inc trades at $237.26 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 4926.7× Aterian Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| ATER | DGX | |
|---|---|---|
Market Cap | $5.32M | $26.21B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $238.50 |
52-Week Low | $0.36 | $173.49 |
Enterprise Value | $5.90M | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $0.489, up 1.88% with a bearish technical signal despite recent earnings beats. The company faces significant financial challenges with negative net income margins (-30.78%) and declining revenue from $221M in 2022 to $69M in 2025. Recent news highlights a pending asset sale that could return $0.85-$1.14 per share to stockholders, creating near-term catalyst potential. Cash flow remains negative at -$13.14M for 2025, though the balance sheet shows $18M cash against $19.3M current liabilities.
The outlook hinges on the proposed asset sale delivering shareholder value, with technical indicators suggesting caution. Investment opportunity exists if the sale completes favorably, but risks include ongoing operational losses, declining revenue, and negative cash flow. Analyst sentiment is split 50/50 buy/hold, reflecting uncertainty about the company's turnaround prospects beyond the immediate transaction.
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
